Success Metrics

Clinical Success Rate
83.3%

Based on 5 completed trials

Completion Rate
83%(5/6)
Active Trials
0(0%)
Results Posted
20%(1 trials)
Terminated
1(17%)

Phase Distribution

Ph phase_1
3
50%
Ph phase_3
1
17%
Ph phase_4
1
17%
Ph phase_2
1
17%

Phase Distribution

3

Early Stage

1

Mid Stage

2

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
3(50.0%)
Phase 2Efficacy & side effects
1(16.7%)
Phase 3Large-scale testing
1(16.7%)
Phase 4Post-market surveillance
1(16.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

83.3%

5 of 6 finished

Non-Completion Rate

16.7%

1 ended early

Currently Active

0

trials recruiting

Total Trials

6

all time

Status Distribution
Completed(5)
Terminated(1)

Detailed Status

Completed5
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
0
Success Rate
83.3%
Most Advanced
Phase 4

Trials by Phase

Phase 13 (50.0%)
Phase 21 (16.7%)
Phase 31 (16.7%)
Phase 41 (16.7%)

Trials by Status

completed583%
terminated117%

Recent Activity

0 active trials
Showing 5 of 6
completedphase_2

Sutent Following Chemotherapy, Radiation and Surgery For Resectable Esophageal Cancer

NCT00400114
terminatedphase_4

Biological, Pathological and Imagery Markers in the First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma

NCT00930345
completedphase_1

A Phase Ib Study of Rad001 and Sutent to Treat Renal Cell Carcinoma

NCT00788060
completedphase_3

Sequential Study to Treat Renal Cell Carcinoma

NCT00732914
completedphase_1

Study Of SU011248 In Combination With Docetaxel In Patients With Metastatic Breast Cancer

NCT00291577
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT00400114Phase 2

Sutent Following Chemotherapy, Radiation and Surgery For Resectable Esophageal Cancer

Completed
NCT00930345Phase 4

Biological, Pathological and Imagery Markers in the First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma

Terminated
NCT00788060Phase 1

A Phase Ib Study of Rad001 and Sutent to Treat Renal Cell Carcinoma

Completed
NCT00732914Phase 3

Sequential Study to Treat Renal Cell Carcinoma

Completed
NCT00291577Phase 1

Study Of SU011248 In Combination With Docetaxel In Patients With Metastatic Breast Cancer

Completed
NCT00904657Phase 1

An Explorative Study on the Pharmacokinetics and Pharmacodynamics of Sunitinib in Healthy Volunteers

Completed

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6